Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome
2007; Wiley; Volume: 23; Issue: 3 Linguagem: Inglês
10.1002/mds.21859
ISSN1531-8257
AutoresMouna Ben Djebara, Yulia Worbe, Michaël Schüpbach, Andréas Hartmann,
Tópico(s)Hereditary Neurological Disorders
ResumoCoprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.
Referência(s)